Literature DB >> 26826616

Peripheral Neuropathy After Fecal Microbiota Transplantation for Clostridium difficile Infection: A Case Report.

Michelle M Didesch1, Allison Averill2, Mooyeon Oh-Park3.   

Abstract

We present a case of a 71-year-old man with Clostridium difficile infection who underwent fecal transplantation. The patient was found to have a predominantly demyelinating sensorimotor peripheral polyneuropathy upon electrodiagnostic testing. To our knowledge, only one case of peripheral neuropathy after fecal transplantation has previously been reported. Although the exact cause of this patient's neuropathy cannot be confirmed, it has been speculated that the pathophysiology is an immune-mediated process. Given the increasing incidence of C difficile infections and the emergence of fecal transplantation as treatment, it is important to note that peripheral neuropathy is a potential adverse complication.
Copyright © 2016 American Academy of Physical Medicine and Rehabilitation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 26826616     DOI: 10.1016/j.pmrj.2016.01.009

Source DB:  PubMed          Journal:  PM R        ISSN: 1934-1482            Impact factor:   2.298


  3 in total

1.  Ethical Considerations in Microbial Therapeutic Clinical Trials.

Authors:  Michael H Woodworth; Kaitlin L Sitchenko; Cynthia Carpentieri; Rachel J Friedman-Moraco; Tiffany Wang; Colleen S Kraft
Journal:  New Bioeth       Date:  2017-10-17

Review 2.  The Gut Microbiome as Therapeutic Target in Central Nervous System Diseases: Implications for Stroke.

Authors:  Katarzyna Winek; Ulrich Dirnagl; Andreas Meisel
Journal:  Neurotherapeutics       Date:  2016-10       Impact factor: 7.620

3.  Neurological manifestations related to Crohn's disease: a boon for the workforce.

Authors:  Reza Nemati; Somayeh Mehdizadeh; Hooman Salimipour; Ehsan Yaghoubi; Zeinab Alipour; Seyed Masoud Tabib; Majid Assadi
Journal:  Gastroenterol Rep (Oxf)       Date:  2017-09-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.